78 results about "Epidemic strain" patented technology

The invention discloses a Newcastle disease vaccine strain with high antibody escape ability and a modification method thereof, the cell strain is preserved in China General Microbiological Culture Collection Center on January 19, 2024, the address of the preservation unit is CGMCC No.45870, No.1 yard, Beichen West Road, Chaoyang District, Beijing, and the classification name of the strain is Newcastle disease virus strain. The recombinant NDV vaccine strain has the same antigen site as the current NDV gene VII type epidemic strain and has the efficient proliferation efficiency superior to that of a classical vaccine strain La Sota, the thermal stability of the NDV vaccine strain is improved by the constructed recombinant vaccine strain, and the cost of vaccine cold-chain transportation is reduced.

The invention discloses a kit and a detection method for detecting an internally-running sheep virus epidemic strain, the kit comprises a crRNA sequence and an RT-RPA primer, the detection method comprises an RT-RPA reaction system and a CRISPR / cas12a reaction system, RT-RPA nucleic acid amplification and CRISPR / cas12a nucleic acid detection are combined, a two-step detection method is adopted, firstly, RT-RPA nucleic acid amplification is carried out, secondly, RT-RPA nucleic acid amplification is carried out, thirdly, RT-RPA nucleic acid amplification is carried out, secondly, CRISPR / cas12a nucleic acid detection is carried out, and thirdly, RT-RPA nucleic acid detection is carried out. Then, the RT-RPA nucleic acid product is added into a CRISPR / cas12a nucleic acid detection system, and the Chinese epidemic strain of the internally-running sheep virus can be detected. The detection method is simple, efficient, low in dependence on instruments and equipment, good in sensitivity, specificity and stability and good in social application prospect.

The invention discloses a primer group for identifying six different genotypes of IBV epidemic strains and a high-resolution melting curve detection method, and relates to the technical field of virus detection. The primer group for identifying the six IBV epidemic strains with different genotypes is HRM-F / HRM-R, and the nucleotide sequences of the primer group are shown as SEQ ID NO. 1 and SEQ ID NO. 2. By utilizing the specific primer group and the detection method disclosed by the invention, qualitative and quantitative analysis on single infection or mixed infection of IBV epidemic strain genotypes of LX4 (GI-19), Mass (GI-I), 4 / 91 (GI-13), LDT3-A (GI-28), Taiwan (GI-7) and CK / CH / LSC / 99I (GI-22) can be realized. The detection sensitivity is high, the specificity is good, the accuracy is high, the operation is simple and rapid, the cost is low, and the method is suitable for popularization.

The invention discloses a fiveleaf virus GII.3 whole genome sequencing primer based on an amplicon sequencing technology and application thereof, and belongs to the technical field of virus gene sequencing. According to the whole genome sequencing primer and the sequencing method for the fiveleaf virus GII.3, interference of other microorganisms on sequencing can be avoided, the gene sequencing depth is high, the advantages of being wider in whole genome coverage, high in detection accuracy and high in specificity are achieved, the sequencing result can reflect mutation characteristics of main epidemic strains of the fiveleaf virus, and the sequencing result can be used for detecting the mutation characteristics of the main epidemic strains of the fiveleaf virus GII.3. And a powerful tool is provided for rapid diagnosis and full prevention of the fiveleaf akebia viruses.

The invention belongs to the field of biology, and discloses an mRNA (messenger ribonucleic acid) with a nucleotide sequence as shown in SEQ ID NO.3. Antiserum of a strain (A / chick / Gansuu / 28 / 2024) corresponding to the mRNA has relatively good reactivity with other strains and poorer reaction with a current vaccine strain RE-13, the branched strain is a current epidemic strain, and the mRNA prepared from the HA gene of the strain has the advantage of strong protection; the invention also aims to provide the mRNA, application thereof and a vaccine.

The application discloses a novel trimeric recombinant protein vaccine. Specifically disclosed are a mutant protein RBD8M with an amino acid sequence of SEQ ID No. 1 and a fusion protein of positions 26-277, positions 1-277 and SEQ ID No. 4. The application also discloses a vaccine containing the fusion protein, and further develops a trimeric recombinant protein vaccine containing the fusion protein and a double adjuvant. Experiments show that the vaccine prepared in the application can effectively induce cellular immunity and humoral immunity of the body in animals, a trace amount of the protein can stimulate a very high immune response of mice, has a good protection effect, can simultaneously produce high-titer neutralizing antibodies against various epidemic strains of the novel coronavirus, is a broad-spectrum effective new coronavirus vaccine, and has important significance for preventing novel coronavirus infection and a wide clinical application prospect.

The invention discloses a porcine epidemic diarrhea and porcine rotavirus (G9 type) bigeminy attenuated vaccine and a preparation method thereof, and relates to the technical field of veterinary biological products. According to the present invention, dominant genotype strains such as PEDV G2 type KQ01 strain (the preservation number is CCTCC NO: V202005) and PoRV G9 type CH09 strain (the preservation number is CCTCC NO: V202191) are adopted as parent strains, a cell continuous passage method is adopted to carry out passage attenuation, and the virus content, the purity, the specificity, the hereditary stability, the safety and the immunogenicity are systematically inspected during the passage process; and then, carrying out proliferation process research on passage attenuated strains PEDV HB17-R and PoRV JS01-R in a bioreactor, harvesting a cell culture, mixing the two antigens according to a proper ratio, adding a proper amount of a stabilizer, and carrying out a freeze vacuum drying process to obtain the high-purity PoRV-HB17-R / PoRV-HB17-R / PoRV-HB17-R / PoRV-HB17-R / PoRV-JS01-R composite antigen. The bigeminy attenuated vaccine is highly matched with current dominant prevalent strains (PEDV G2 type and PoRV G9 type), is based on a suspension culture technology and has both safety and high efficiency.

The present disclosure provides a type A foot-and-mouth disease virus-like particle antigen assembled by VP2, VP3 and VP1 antigen proteins of an epidemic strain of type A foot-and-mouth disease virus. The type A foot-and-mouth disease virus VP2 antigen protein is encoded by a nucleotide sequence shown in SEQ ID No. 1 or its degenerate sequence, the type A foot-and-mouth disease virus VP3 antigen protein is encoded by a nucleotide sequence shown in SEQ ID No. 2 or its degenerate sequence, and the type A foot-and-mouth disease virus VP1 antigen protein is encoded by a nucleotide sequence shown in SEQ ID No. 3 or its degenerate sequence.

The invention discloses a porcine epidemic diarrhea virus G2c genotype strain as well as a separation method and application thereof. Aiming at the current epidemic PEDV variant strain, the genetic variation rule of the epidemic strain is clarified by carrying out virus separation, identification and pathogenicity analysis, and the method has important significance on epidemiology, vaccine development and the like of the PEDV. Specifically, an applicant successfully separates a PEDV strain capable of realizing stable passage propagation in Vero-CCL81 cells from intestinal contents of diarrhea piglets collected from a pig farm of Jiangpermanent Province in Hunan, the PEDV strain is identified and determined as a porcine epidemic diarrhea virus G2c subtype, the PEDV strain is named PEDV CH / HNJY / 2025, the PEDV strain is preserved in China General Microbiological Culture Collection Center on December 11, 2025, and the preservation number of the PEDV strain is CGMCC NO. The preservation number is CGMCC (China General Microbiological Culture Collection Center)

The invention discloses a canine parvovirus CPV-2c subtype virus strain and application thereof, and relates to the technical field of biology. The canine parvovirus CPV-2c subtype virus strain is preserved in the China Center for Type Culture Collection on November 12, 2024, the preservation address is Wuhan University, Wuhan, China, and the preservation number is CCTCC NO: V202492. Genetic evolution analysis shows that the canine parvovirus CPV-2c subtype virus strain obtained through separation has a better genetic relationship with other epidemic strains published domestically. The strain has good pathogenicity, can show typical CPV clinical symptoms when infected dogs, has great advantages for verifying therapeutic drugs and evaluating vaccine efficacy in vivo, and plays an important role in research and development of the therapeutic drugs and vaccines. In addition, the strain can be cultured and proliferated in vitro and has the potential of being developed into vaccines.

This invention belongs to the field of biomedical technology, specifically relating to a method for constructing a highly cell-adaptive PEDV GIIc recombinant chimeric virus. Specifically, this invention, based on the PEDV viral S protein determining PEDV's cell adaptability, innovatively elucidates that S2 is the key subunit determining its cell adaptability. On this basis, this invention proposes a scheme that can increase viral titer and thus reduce vaccine production costs when preparing candidate vaccine strains of circulating PEDV strains (especially GIIc). This involves retaining the S2 subunit of the highly cell-adaptive strain and replacing the S1 subunit of the highly cell-adaptive strain with the S1 subunit of the circulating strain, or replacing the S2 subunit of the circulating strain with the S2 subunit of the highly cell-adaptive strain. This scheme can both preserve the immunogenicity of the circulating strain and improve the efficiency of high-titer vaccine production.

The invention relates to the field of veterinary biological products, in particular to a feline panleukopenia virus and application thereof. The preservation number of the feline panleucopenia virus 708 strain is CCTCC No.V202320, and the feline panleucopenia virus 708 strain belongs to existing epidemic strains, has good immunogenicity and can provide effective immune protection for epidemic strains in different regions.

The application provides a monoclonal antibody for specifically detecting rotavirus and an application thereof, and is directed to epidemic strains of porcine rotavirus, and refers to the gene sequence of VP6 protein published in GenBank, further optimizes an antigen epitope, obtains a purified recombinant VP6 protein with antigenicity, and performs animal immunization, and successfully screens the monoclonal antibody capable of specifically recognizing the porcine rotavirus. The monoclonal antibody screened can effectively recognize the epidemic strains, has the broad-spectrum recognition, is superior to the commercially available antibody, has high antigen recognition target specificity, is low in non-specificity, and has clear sequence background, can be scaled up and produced, and has good commercial value.

The invention provides a porcine pseudorabies virus antigen as well as a preparation method and application thereof, and relates to the technical field of biology, the antigen comprises porcine pseudorabies virus gD protein; the amino acid sequence of the porcine pseudorabies virus gD protein is shown as SEQ ID NO.5. Experiments prove that the porcine pseudorabies virus antigen is good in antigenicity, easy to highly express and good in broad spectrum, and the generated antibody is high in neutralizing capacity for current epidemic strains. The porcine pseudorabies virus antigen provided by the invention is easy to highly express, and the expression quantity of the antigen in fermentation liquor after recombinant cells are subjected to fermentation culture is obviously improved. The technical problem that in the prior art, the expression quantity of antibodies generated by commercial vaccine immunization is low is solved.

The present invention provides a recombinant RBD trimer protein capable of simultaneously generating cross neutralization activity for various severe acute respiratory syndrome coronavirus 2 (SARS-COV-2) epidemic strains. The RBD trimer protein is taken as an antigen and supplemented with an adjuvant to immunize an organism, so that a high-titer neutralizing antibody aiming at various SARS-COV-2 epidemic strains can be generated at the same time, and the antibody has a certain broad-spectrum property and can be used for treating and / or preventing SARS-COV-2 infection and / or coronavirus disease 2019.

The application relates to the field of biological medicine, and provides a tetravalent antibody for neutralization of a novel coronavirus, which comprises an antibody monomer nAb and an scFv structure coupled at the Fc end of the heavy chain of the antibody monomer through a linker 1. Compared with the nAb antibody, the tetravalent antibody has higher antiviral capacity for various epidemic strains of the novel coronavirus, and has good application value.

The invention discloses a recombinant bacillus calmette-guerin vaccine for expressing O and A type multi-epitope fusion peptides of foot and mouth disease viruses and application of the recombinant bacillus calmette-guerin vaccine, and belongs to the field of biotechnology and veterinary vaccines. The amino acid sequence of the multi-epitope fusion peptide is shown as SEQ ID NO: 1, the multi-epitope fusion peptide comprises dominant immune T cell and B cell antigen epitopes from a plurality of O-type and A-type foot-and-mouth disease virus epidemic strains, and a mycobacterium signal peptide is fused at the N terminal. The recombinant strain rBCG-MIPGA is successfully constructed by carrying out codon optimization on the fusion gene, cloning the fusion gene to a pMV306 vector and carrying out electrotransfection on BCG. The recombinant BCG can simultaneously excite high-titer specific antibodies aiming at foot-and-mouth disease virus type O and type A and remarkable T cell immune response, shows lasting and broad-spectrum protection potential, and has great application value in the aspect of preparing safe, efficient and broad-spectrum foot-and-mouth disease vaccines.

The application provides a general avian infectious bronchitis virus whole genome deep sequencing method and application. The method realizes efficient amplification of long fragments of whole genomes of different genotype IBV epidemic strains by designing and applying a set of combinations containing 24 pairs of specific primers. The specific sequences of the primer combinations are shown in SEQ NO:1 to SEQ NO:48. Compared with a traditional sequencing method, the application significantly reduces the sequencing cost. Only two PCR reactions are needed, and more than 27 kb of IBV full-length genome sequence can be successfully obtained, which provides a more economical and efficient solution for IBV related scientific research and molecular epidemiology monitoring, and helps to promote the development of related field scientific research.

The invention relates to an anti-HIV broad-spectrum neutralizing antibody with an ADCC effect and application of the anti-HIV broad-spectrum neutralizing antibody in treatment and / or prevention of HIV infected diseases. The antibody FD22 disclosed by the invention shows broad-spectrum and strong neutralizing capacity on different subtype HIV-1 pseudoviruses which are prevalent globally, and particularly shows excellent neutralizing activity on HIV-1AE and BC subtype strains which are prevalent widely in China. The antibody FD22 is an effective supplement for the existing HIV neutralizing antibody drug library, and can provide more comprehensive prevention and treatment choices for Chinese epidemic strains. Meanwhile, the antibody FD22 can promote expression of NK cell activating factors, activate NK cells and improve the degranulation effect of the NK cells, so that the killing effect of immune cells such as the NK cells on HIV infected cells is enhanced, and the potential of treating HIV infection is shown.

The application provides a pair of mouse monoclonal antibodies 4A5 and 2C12 with specific binding to canine rotavirus VP7 protein, and a colloidal gold detection kit prepared from the mouse monoclonal antibodies, which can detect various epidemic strains and standard strains of canine rotavirus with high sensitivity, has a high coincidence rate with an RT-PCR detection method, and can detect epidemic strains and target strains in different regions, has the advantages of rapidness, simplicity, accuracy, and can meet the urgent needs of the present clinical stage.

The application provides a primer probe combination for identifying the genotype of African swine fever virus, comprising a primer probe combination a for identifying a B646L gene, a primer probe combination b for identifying an MGF-110-5L gene and a primer probe combination c for identifying an I177L gene. The method for identifying the genotype of African swine fever virus by using the primer probe combination is as follows: extracting the genomic DNA of a sample to be detected, using the extracted genomic DNA of the sample to be detected as a template, performing a triple fluorescent quantitative PCR reaction by using the primer probe combination, and judging the genotype of African swine fever virus according to the fluorescent signal. The application also provides the application of the primer probe combination to the preparation of a kit for identifying the genotype of African swine fever virus. The concentration and reaction conditions of the primer probe combination are optimized, so that the designed primer probe combination has strong specificity, sensitivity and repeatability, not only solves the identification problem of African swine fever virus, but also simultaneously realizes the synchronous identification of three kinds of epidemic strain genotypes.

The invention relates to a preparation method of an HIV-1CRF 5501B gp140 trimer in the field of protein engineering, which comprises the following steps: culturing recombinant expression cells of fusion protein, and collecting supernatant; the fusion protein comprises an HIV (human immunodeficiency virus)-1CRF 5501B gp140 as shown in SEQ ID NO. 1 and a purification tag; loading the supernatant to a purification label affinity chromatography column, balancing, eluting, and collecting the eluate; carrying out dialysis and ultrafiltration on the eluent, and collecting a concentrated solution; and purifying the concentrated solution by adopting a volume exclusion chromatography method to prepare the HIV-1CRF 5501B gp140 tripolymer. The application focuses on the unique epidemic strain HIV-1CRF 5501B, provides the preparation method of the unique epidemic strain gp140 trimer, and has important clinical value for analyzing different HIV subtypes in the aspects of epidemiology, disease treatment and the like.

The invention relates to the technical field of biology, and particularly provides an influenza virus live vaccine as well as a preparation method and application thereof. The invention aims to solve the problems that influenza vaccines in the prior art generally face ineffective single immunization, cellular immune deficiency, insufficient broad-spectrum protection and high safety risk. Therefore, the invention provides an influenza virus live vaccine which comprises influenza virus which is not subjected to attenuation treatment. The influenza virus live vaccine disclosed by the invention breaks through the safety limitation of the traditional attenuated live vaccine, the fact that an unattenuated influenza epidemic strain (such as an H1N1 PR8 strain) can realize safe and efficient immune response through subcutaneous inoculation is proved for the first time, and a brand new technical path is provided for the development of influenza vaccines.

The present invention discloses a monoclonal antibody for distinguishing a lapinized attenuated vaccine strain of classical swine fever from an epidemic strain and its application, belonging to the field of immunoglobulins. Specifically disclosed is an E2 protein monoclonal antibody or an antigen-binding fragment thereof, including a heavy chain variable region (SEQ ID No.1) and a light chain variable region (SEQ ID No.3). The present invention also discloses an ELISA method for distinguishing a lapinized attenuated vaccine strain of classical swine fever from an epidemic strain using the E2 protein monoclonal antibody. The monoclonal antibody of the present invention specifically reacts with an epidemic strain of classical swine fever virus, but does not react with a lapinized attenuated vaccine strain of classical swine fever. The ELISA competition method established using the monoclonal antibody can accurately distinguish a lapinized attenuated vaccine strain of classical swine fever from an epidemic strain. The monoclonal antibody of the present invention can be used in the fields of serological diagnosis of CSFV immunization and wild virus, immune effect evaluation, and related experiments, and provides antibody resources for effective detection and purification of CSFV.

The invention relates to a multiplex fluorescent genotyping detection primer probe group and a kit aiming at a norovirus epidemic strain, and belongs to the technical field of biology. The primer probe group comprises a primer pair and a probe which are used for detecting the GII.17 type, the GII.3 type and the GII.4 type of the noroviruses; wherein the nucleotide sequences of the primer pair and the probe for detecting the GII.17 type are as shown in SEQ ID NO: 1-3; the nucleotide sequences of the primer pair and the probe for detecting the GII.3 type are as shown in SEQ ID NO: 4-6; the nucleotide sequences of the primer pair and the probe for detecting the GII.4 type are as shown in SEQ ID NO: 7-9. The method has the following technical effects: 1, the detection time is short, the operation is simple and convenient, and the total detection time is about 1.5 hours; 2, the sensitivity is high; 3, the detection limit is low, and the method can be applied to environmental specimen detection.

The invention relates to a duck infectious serositis pentavalent inactivated vaccine as well as a preparation method and application thereof. The vaccine is prepared from a duck infectious serositis type 1 antigen, a duck infectious serositis type 2 antigen, a duck infectious serositis type 6 antigen, a duck infectious serositis type 7 antigen and a duck infectious serositis type 10 antigen. The preparation method comprises the following steps: S1, strain screening; step S2, strain culture; step S3, carrying out inactivation treatment; step S4, bacterial liquid mixing; and S5, emulsifying the adjuvant. The duck infectious serositis pentavalent inactivated vaccine has the advantages of prominent broad spectrum, excellent immune effect and high industrial feasibility, can cover more than 90% of epidemic strains, solves the problem of incomplete prevention of the existing vaccine, has protection rates of more than or equal to 90% on the attack of five serotype virulent poison, adopts a fermentation tank for amplification culture in a culture process, has stable bacterial liquid proliferation efficiency, and is suitable for large-scale production. Emulsifying process parameters are clear and suitable for large-scale production.

The invention discloses a recombinant Newcastle disease virus, avian influenza virus (H9 subtype) and avibacterium paragallinarum (type A + type B + type C) triple inactivated vaccine as well as preparation and application thereof, and relates to the technical field of bioengineering. Comprising the following steps: culturing a recombinant Newcastle disease virus DC7 strain on a BHK-21-sc suspension cell to obtain a Newcastle disease virus solution, culturing an H9 subtype avian influenza virus on an MDCK-sc suspension cell to obtain an avian influenza virus solution, and carrying out fermentation culture on an avibacterium paragallinarum DC-A strain, a DC-B strain and a DC-C strain to obtain a fermentation bacteria solution. Inactivating the virus liquid and the bacterium liquid, and mixing according to a certain proportion to prepare a triple inactivated vaccine; the triple inactivated vaccine is good in safety and can be used for preventing the Newcastle disease, the H9 subtype avian influenza and the A, B and C serotype avibacterium paragallinarum diseases, immunization does not cause reduction of the laying rate, meanwhile, the antibody level of the Newcastle disease and the H9 subtype avian influenza is high, and the protection of the vaccine on the A, B and C serotype avibacterium paragallinarum epidemic strains and variants can reach 100%.

The application provides a kind of construction and application of PRRSV live vector vaccine strain of recombination expression PEDV S protein receptor RBD domain, and the results show that the dominant antigen region of PEDV S protein RBD function domain can be expressed in the recombination virus rHuN4-F112-SRBD1 rescued, and the biological characteristics of recombination virus are similar to parent virus.The nucleotide sequence of SRBD1 gene introduced in each generation of recombination virus and the amino acid sequence encoded thereby are not deleted or mutated, and the IFA and Western Blot detection results show that the SRBD1 gene introduced in different generations of recombination virus rHuN4-F112-SRBD1 can be stably expressed, and does not affect the expression of parent virus itself protein, indicating that the recombination virus rHuN4-F112-SRBD1 strain has genetic stability.The immunogenicity analysis of recombination virus rHuN4-F112-SRBD1 shows that the recombination virus rHuN4-F112-SRBD1 strain can induce specific antibodies against PEDV S protein and PRRSV2 in piglets after immunization, and the antibodies induced have neutralizing effect on PEDV epidemic strain, and can be used for the development and development of PRRS and PED novel genetic engineering vaccine.

The application discloses a broad-spectrum neutralizing pig-derived monoclonal antibody of type A foot-and-mouth disease virus (FMDV) and application thereof. The antibody PAF56 has an amino acid sequence of a heavy chain variable region as shown in SEQ ID No. 12, a heavy chain CDR1 sequence of GFGFSNTY, a heavy chain CDR2 sequence of VFTGGGAT, and a heavy chain CDR3 sequence of VSNRDGFGGVGNV. The antibody PAF56 has an amino acid sequence of a light chain variable region as shown in SEQ ID No. 13, a light chain CDR1 sequence of SGSVTSLNY, a light chain CDR2 sequence of RTN, and a light chain CDR3 sequence of ALYKGSGTDTNI. The antibody PAF56 can simultaneously neutralize an AF72 strain of an A22 lineage and A / WH / CHA / 09 and A / GDMM / 2013 epidemic strains of a domestic SEA97 lineage, and has broad-spectrum neutralization activity of type A FMDV. The antibody PAF56 recognizes an antigen site 2 of a VP2 B-C loop, and a key amino acid is VP2 D72; the recognized site is highly conserved in type A FMDV. The application first obtains a broad-spectrum neutralizing antibody of type A specific FMDV from a natural host and identifies a key antigen site recognized by the antibody, thereby providing a powerful tool for antigen structure analysis of FMDV and establishment of a serological detection method.

The invention discloses a polypeptide drug for resisting porcine reproductive and respiratory syndrome virus infection and application of the polypeptide drug, and belongs to the technical field of porcine reproductive and respiratory syndrome virus resistance. The invention aims to provide a novel polypeptide drug for resisting porcine reproductive and respiratory syndrome virus infection, which is used for antagonizing the porcine reproductive and respiratory syndrome virus infection. The invention provides a polypeptide for resisting porcine reproductive and respiratory syndrome virus infection. The polypeptide is obtained by taking an amino acid sequence as shown in SEQ ID NO.9 or SEQ ID NO.10 as a starting sequence and performing insertion, mutation or deletion on any site. The polypeptide can inhibit combination of PRRSV epidemic strains with different branches and target cells, and has good broad spectrum.